Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy.

ESMO Open · 2025 · PMC12414891 · PMID 40882247

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)

Overall, receipt of any adjuvant therapy versus no adjuvant therapy ( n = 298) showed a trend toward improved outcomes for RFS (HR 0.79, 95% CI 0.62-1.0, P = 0.06) and DRFS (HR 0.78, 95% CI 0.61-1.004, P = 0.06), and statistically significant improvement in OS (HR 0.71, 95% CI 0.54-0.93, P = 0.01).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.